clinical dataProQR validates RNA editing platform and raises $59.2mProQR has reported the first clinical target-engagement data for its Axiomer RNA editing platform, while pricing a share offering and concurrent private placement that includes existing partner Eli … more ➔
licensingRecordati secures ex-U.S. rights to Ionis’ Alexander disease therapyItalian pharma Recordati has entered into a license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and marketing rights to zilganersen, an investigational RNA-targeted medicine … more ➔
EmploymentADC Therapeutics cuts 17% of staff after safety setbackADC Therapeutics will cut about 17% of its global workforce as it tries to preserve cash and keep Zynlonta’s regulatory strategy on track after a difficult Phase III readout. more ➔
licensingNovartis signs up to $1.9bn deal to tap Antares’ undruggable-target engineNovartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring … more ➔
fundraisingLeyden Labs adds €40m for intranasal flu preventionDutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses. more ➔
fundraisingRQ Bio raises $115m for long-acting flu antibodyLondon’s RQ Bio, a private biotech developing long-acting antibody therapeutics to prevent flu, has raised $115 million (£85.5 million/€101 million) in its Series A financing. more ➔
M&AThalia buys Sanmirna, becomes a clinical-stage RNA companyThalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten … more ➔
Start-upMerck launches build-to-buy Saturnus Bio with $50mMerck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies. more ➔
Start-upTRIMTECH extends seed round to $47M for protein degradation drugsUK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million. more ➔
Market accessAfter FDA rejection, Sanofi’s BTK inhibitor wins EU approvalSanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous … more ➔
